Company intelligence / Profile preview
Menarini Group
Florence, Italymenarini.com ↗
- Ownership
- Private
- Employees
- ~17000
- Development stage
- Commercial
01
Overview
Menarini has a robust commercial portfolio across multiple therapeutic areas including oncology—where it markets Tagraxofusp for BPDCN—and recently received FDA & EMA approval for Elacestrant in advanced/metastatic breast cancer. The pipeline includes both small molecules and biologics targeting high unmet needs such as antimicrobial resistance and rare cancers. The group also develops advanced diagnostic platforms for precision medicine applications
- Therapeutic areas
- GastroenterologyPulmonologyCardiovascularOncologyNeurologyInfectious Diseases
- Modalities
- Small moleculesbiologics (including monoclonal antibodies)targeted therapiesdiagnostics
- Industry
- Pharma
02
Drug pipeline
19 assets18 more assets in the full pipeline.
03
Partnerships
Collaborations with Oxford BioTherapeutics on next-generation cancer drugslicensing agreements with Ryvu Therapeutics for SEL24 AML programpartnerships with academic institutions globally for R&D initiatives
Beyond the preview
Go deeper on Menarini Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Menarini Group.